Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Connect Biopharma Holdings (CNTB) Shares Outstanding (Diluted Average) (2023 - 2025)

Historic Shares Outstanding (Diluted Average) for Connect Biopharma Holdings (CNTB) over the last 3 years, with Q3 2025 value amounting to $55.7 million.

  • Connect Biopharma Holdings' Shares Outstanding (Diluted Average) rose 83.61% to $55.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.7 million, marking a year-over-year increase of 83.61%. This contributed to the annual value of $55.2 million for FY2024, which is 26.51% up from last year.
  • Latest data reveals that Connect Biopharma Holdings reported Shares Outstanding (Diluted Average) of $55.7 million as of Q3 2025, which was up 83.61% from $55.5 million recorded in Q2 2025.
  • Connect Biopharma Holdings' Shares Outstanding (Diluted Average)'s 5-year high stood at $55.7 million during Q3 2025, with a 5-year trough of $55.1 million in Q4 2023.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $55.4 million, with a median of $55.3 million in 2024.
  • Data for Connect Biopharma Holdings' Shares Outstanding (Diluted Average) shows a peak YoY increase of 83.61% (in 2025) and a maximum YoY decrease of 38.05% (in 2025) over the last 5 years.
  • Quarter analysis of 3 years shows Connect Biopharma Holdings' Shares Outstanding (Diluted Average) stood at $55.1 million in 2023, then grew by 0.27% to $55.2 million in 2024, then grew by 0.91% to $55.7 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $55.7 million for Q3 2025, versus $55.5 million for Q2 2025 and $55.4 million for Q1 2025.